BRCR global

Futó vizsgálatok

• Toboroz

  Phase I Study of SYS6043 in Patients With Advanced/Metastatic Solid Tumors

  NCT07424547· 1. fázis· Forrás

• Toboroz

  This is a Study to Learn About How the Combination of the Study Medicines Sigvotatug Vedotin Plus Pembrolizumab Works in People With Non-small Cell Lung Cancer With High Levels of PD-L1.

  NCT06758401· 3. fázis· Forrás

• Toboroz

  Study of Daraxonrasib (RMC-6236) in Patients With RAS Mutated NSCLC (RASolve 301)

  NCT06881784· 3. fázis· Forrás

• Fut, nem toboroz

  A Study of Valemetostat Tosylate Plus Pembrolizumab Versus Pembrolizumab Alone in First-Line NSCLC Without Actionable Genomic Alterations

  NCT06644768· 1/2. fázis· Forrás

• Toboroz

  MagnetisMM-32: A Study to Learn About the Study Medicine Called Elranatamab in People With Multiple Myeloma (MM) That Has Come Back After Taking Other Treatments (Including Prior Treatment With an Anti-CD38 Antibody and Lenalidomide)

  NCT06152575· 3. fázis· Forrás

• Toboroz

  A Study of DB-1310 in Advanced/Metastatic Solid Tumors

  NCT05785741· 1/2. fázis· Forrás

• Fut, nem toboroz

  Vepdegestrant (ARV-471/PF-07850327) + Palbociclib vs Letrozole + Palbociclib in ER(+)/HER2(-) Advanced Breast Cancer

  NCT05909397· 3. fázis· Forrás

• Fut, nem toboroz

  Phase III Study of AK112 for NSCLC Patients

  NCT06396065· 3. fázis· Forrás

• Fut, nem toboroz

  A Study of YL202 in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer and Breast Cancer

  NCT05653752· 1. fázis· Forrás

• Fut, nem toboroz

  To Evaluate Efficacy and Safety of Serplulimab + Chemotherapy (Carboplatin- Etoposide) in US Patients With ES-SCLC

  NCT05468489· 3. fázis· Forrás

• Toboroz

  ZEN003694 and Enzalutamide Versus Enzalutamide Monotherapy in Metastatic Castration-Resistant Prostate Cancer

  NCT04986423· 2. fázis· Forrás

• Fut, nem toboroz

  A Study of Encorafenib Plus Cetuximab With or Without Chemotherapy in People With Previously Untreated Metastatic Colorectal Cancer

  NCT04607421· 3. fázis· Forrás

Egyszerre toboroz

Hány vizsgálat toboroz itt egyszerre ugyanarra az indikációra. Darabszám, nem értékelés.

• Prosztatarák3 toboroz
• Tüdőrák3 toboroz
• Fej-nyaki daganatok1 toboroz
• Mielóma multiplex1 toboroz
• Petefészekrák1 toboroz

Kutatók

Ide még nem kötődik kutató.